PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

NCT00045942 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: Itraconazole
DRUG: PKC412

Sponsor

Novartis Pharmaceuticals